Antibiotic Time-Out: The 48-72 Hour Structured Review

An antibiotic time-out is a structured, prospective reassessment of an antibiotic regimen conducted 48–72 hours after therapy begins — the point at which culture and susceptibility results, imaging, and the patient’s clinical trajectory are typically all available to inform a real decision. It is a specific antimicrobial-stewardship intervention, not a synonym for a stewardship program overview: a hospital can have a fully structured stewardship program (leadership, pharmacy expertise, tracking, reporting) and still lack a working time-out process, because the time-out lives inside the treating team’s own daily workflow rather than in a separate stewardship-pharmacist review. This guide is written for infection preventionists, patient-safety officers, quality directors, and risk managers who need to design, trigger, and measure the time-out as a discrete process — not for the treating clinicians performing it.

What the Time-Out Is (and Is Not)

The time-out asks the prescriber — usually with pharmacist input — to stop and formally reconsider a regimen that was started empirically, before enough information existed to know the causative organism, its susceptibility pattern, or how the patient would respond. It is deliberately timed to the window when that information is normally available: most blood and urine cultures finalize within 48–72 hours, and a patient’s clinical trajectory (fever curve, hemodynamics, white count) is usually clear enough by then to support de-escalation, continuation, or discontinuation.

It is commonly confused with prospective audit-and-feedback, but the two are structurally different interventions. Audit-and-feedback is performed by the stewardship team — a pharmacist or physician reviewing charts outside the treating team’s own workflow and feeding recommendations back, often for a defined subset of drugs or patients. The time-out is performed by the treating team itself, built into rounds or the medication order, and applies by default to essentially every patient on antibiotics past 48–72 hours rather than to a targeted review list. A hospital can run one, both, or neither; they are not interchangeable ways of satisfying the same requirement.

Who Conducts It

• The prescriber (attending, resident, or advanced practice provider) makes the actual decision — continue, narrow, switch route, or stop — because only the treating clinician can weigh the full clinical picture.
• The bedside or unit pharmacist typically prompts the review, often by flagging the chart at the 48–72 hour mark, pulling the culture/susceptibility result into the note, and asking the four structured questions below directly during rounds.
• The stewardship team designs the trigger mechanism (the order-set stop date, the EHR alert, the rounding checklist) and monitors whether time-outs are actually happening and being documented — but does not typically perform the individual review itself. This is the design/oversight role that puts the intervention inside a patient-safety or quality function’s remit even though the clinical decision sits with the treating team.
• Nursing is sometimes the trigger point in checklist-based implementations, flagging antibiotic day 3 during medication reconciliation or rounds, without making the clinical call.

The Four Structured Decision Prompts

Time-out tools vary by hospital, but they converge on the same four questions, asked in this order:

1. Does this patient still have an infection that requires antibiotics? Some empiric starts turn out, on 48–72 hour review, to have been for a non-infectious process or a self-limited condition — the correct action is discontinuation, not narrowing.
2. Is the current regimen still the right one, given culture and susceptibility data? This is the de-escalation question: narrowing from broad empiric coverage to a targeted agent once the organism and its susceptibility pattern are known, or escalating if the isolate is resistant to what was started.
3. Can the regimen be simplified? IV-to-oral conversion once the patient is hemodynamically stable and tolerating oral intake, dose adjustment for renal or hepatic function, and consolidating to the fewest agents that still cover the confirmed or suspected organism.
4. What is the total intended duration, and has a stop date been set? The time-out is also where an open-ended order gets a defined end point, rather than continuing by default until someone separately decides to stop it.

The output of each time-out should be a documented decision on all four questions — not just a note that “the case was reviewed.” An undocumented time-out is functionally unmeasurable, which matters for the reasons in the measurement section below.

Building the Trigger Into Clinical Workflow

The time-out only happens reliably if something forces it onto the team’s attention at the right moment, rather than depending on someone remembering. Common trigger mechanisms:

• Order-set stop dates — antibiotic orders default to a 48–72 hour automatic stop or require re-authorization, forcing a decision rather than allowing indefinite continuation by default.
• EHR best-practice advisories — an alert fires when a patient crosses the 48–72 hour mark on a given antibiotic, prompting the prescriber or pharmacist to complete the four-question review before continuing the order.
• Structured rounding checklists — the time-out becomes a standing agenda item on multidisciplinary or ICU rounds for every patient on antibiotics past day 2, independent of an EHR trigger.
• Pharmacist-driven chart flags — the unit or stewardship pharmacist maintains a running list of patients approaching the 48–72 hour window and proactively raises the review, which is often the most reliable trigger in hospitals without EHR-level automation.

Whichever mechanism a hospital uses, the review and its four-question outcome should be captured somewhere retrievable — a structured note field, a stewardship dashboard entry, or a checklist artifact — not left as an undocumented verbal conversation during rounds.

Measuring the Time-Out as a Stewardship Intervention

Because the time-out is one specific action under CDC’s Core Elements Action component (see the broader antimicrobial stewardship program structure this sits inside), it should be tracked and reported the way any other stewardship intervention is — not treated as self-evidently happening just because a policy says it should.

• Process measure: the percentage of eligible antibiotic orders with a documented time-out completed by hour 72 — the most direct signal of whether the trigger mechanism is actually working.
• Outcome measures: de-escalation rate following the time-out window, IV-to-oral conversion rate, and days of therapy or Defined Daily Dose trends before and after implementation — the same metrics a stewardship program already tracks under the Core Elements Tracking and Reporting components, cut specifically to the time-out population.
• A stalled or unmeasured time-out process usually shows up first as a gap between how often staff report “we do time-outs” in interviews and how often a documented decision actually appears in the chart at 48–72 hours — worth auditing directly rather than taking adherence on faith.

Report time-out metrics to the same audiences the broader stewardship program already reports to — prescribers, pharmacy, and hospital leadership — so the intervention doesn’t become an invisible sub-process inside a program that otherwise reports cleanly.

Frequently Asked Questions

Is the antibiotic time-out the same as antibiotic stewardship?

No. Stewardship is the overall program — leadership, pharmacy expertise, tracking, reporting, and so on. The time-out is one specific action a program can implement, alongside others like prospective audit-and-feedback or facility-specific treatment guidance. A program can exist without a working time-out process, and a time-out process is not itself a complete stewardship program.

Why 48–72 hours specifically, and not 24 or 96?

It’s timed to when the information needed to make a real decision is normally available: most blood and urine cultures finalize in that window, and a patient’s clinical response — fever trend, hemodynamics, white count trajectory — is usually clear enough by then. Reviewing earlier often means reviewing before there’s anything new to decide on; waiting longer delays a decision the data already supports.

Who is responsible if a time-out doesn’t happen?

Clinically, the treating prescriber owns the antibiotic decision. Operationally, whoever owns the trigger mechanism — the pharmacist maintaining the flag list, the EHR alert build, the rounding checklist owner — owns whether the review reliably gets prompted in the first place. Distinguishing those two accountabilities matters when a time-out process isn’t working: the fix is usually to the trigger, not a reminder to prescribers.

Does the time-out replace prospective audit-and-feedback?

No, they are complementary, not substitutes. The time-out is default and treating-team-driven; audit-and-feedback is targeted and stewardship-team-driven, often reserved for specific high-risk drugs, patients, or units. Many programs run both.

How should a time-out be documented?

As an answer to all four structured questions — infection still present, regimen still appropriate, simplification possible, duration/stop date set — in a retrievable place (a structured note field or stewardship dashboard entry), not as an unstructured note that a review “occurred.”

Related CASRAI content: the antimicrobial stewardship program guide for the full CDC Core Elements structure this intervention sits inside, the antibiogram guide for the susceptibility data a time-out decision often depends on, and the infection preventionist role guide for how this work is staffed alongside surveillance duties. See also the Patient Safety & Infection Prevention hub, and the medication use evaluation guide for the related but distinct process of evaluating one agent against approved criteria for P&T reporting.